Clinical Trials Snapshot

Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma

Phase 1, single center, open-label study to establish a safe dose (ie, number of cells/kg) of autologous iC9.GD2.CAR.IL-15 T-cells in pediatric patients with relapsed or refractory neuroblastoma.

Phase 1, single center, open-label study to establish a safe dose (ie, number of cells/kg) of autologous iC9.GD2.CAR.IL-15 T-cells in pediatric patients with relapsed or refractory neuroblastoma.